Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a pilot study on safety and efficacy of umbilical cord blood therapy for patients with Hutchinson Gilford Progeria syndrome (HGPS). This is an 1 year trial with 3 IV infusions (4 months apart from each infusion) of umbilical cord blood units with oral Sirolimus to see the safety and efficacy.
This is a pilot study on safety and efficacy of umbilical cord blood therapy for patients with Hutchinson Gilford Progeria syndrome (HGPS). HGPS is a rare genetic disease where affected LMNA gene coding lamin A protein leads to premature aging and early death.
Teenagers with HGPS are in high risk of atherosclerosis and ischemic stroke, and these are major reason of mortality in HGPS.Currently, there are no definite cure for this rare genetic disease. Among the potential drugs under investigation, Lornafarnib (farnesyltransferase inhibitor) lowered the carotid-femoral pulse wave velocity (cfPWV) and also lowered mortality.
Stem cell therapy has proven its efficacy in progeria mouse model. We are trying to study safety and efficacy of umbilical cord blood therapy in human HGPS patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| UCB injection group | Experimental | This pilot study includes only 2 subjects who are enrolled by invitation. Both subjects are included in this single arm. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Umbilical Cord Blood Unit | Drug | 3 infusions of umbilical cord blood (UCB) unit (TNC > 2.0â…¹107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion) |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline Carotid-femoral pulse wave velocity at 48 weeks | measured by carotid doppler ultrasonography | 48 weeks after UCB infusion |
| Change from baseline serum HDL cholesterol at 48 weeks | taken on routine lab | 48 weeks after UCB infusion |
| Change from baseline weight at 48 weeks | measured by bioimpedance analysis | 48 weeks after UCB infusion |
| Measure | Description | Time Frame |
|---|---|---|
| Ankle-brachial index | measured by automatic blood pressure gauge | baseline, 48 weeks after UCB infusion |
| Body fat proportion | taken by bioimpedance analysis |
Not provided
This is a pilot study including 2 patients with HGPS.
Inclusion Criteria:
Exclusion Criteria:
those who show definite hemorrhage or ischemia on brain MRI
those who are affected with systemic infection during study enrolling period
those who are not able to able to make consents to the study; those who are not accompanying any guardians
those who were enrolled in other clinical trials within last 30 days
those who are not appropriate according to laboratory criteria
those who are diagnosed with other malignancies
those who are affected by other serious medical (cardiopulmonary, gastrointestinal, endocrinologic, etc.) conditions
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Min Young Kim, MD, PhD | CHA University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bundang CHA Medical Center | Seongnam-si | Gyeonggi-do | 13496 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011371 | Progeria |
| ID | Term |
|---|---|
| D000083083 | Laminopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008661 | Metabolism, Inborn Errors |
Not provided
Not provided
| ID | Term |
|---|---|
| D020123 | Sirolimus |
| ID | Term |
|---|---|
| D018942 | Macrolides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| baseline, 48 weeks after UCB infusion |
| Range of motion | measured manually | baseline, 48 weeks after UCB infusion |
| height | measured by bioimpedance analysis | baseline, 48 weeks after UCB infusion |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |